Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the competitive advantage of Qian Dama through its "community small store + daily clearance mechanism + warehouse and cold chain" model, which enhances supply stability and operational efficiency [3][24][35] - The report emphasizes the importance of emotional consumption themes and identifies high-quality companies in high-growth sectors, recommending specific companies across various segments [6][37] Summary by Sections Industry Overview - The retail and social service indices reported a decline of 1.47% and an increase of 1.53% respectively during the week of January 12-16, 2026 [5][13] - The internet e-commerce sector showed the highest growth, with a year-to-date increase of 11.18% [16][19] Company Highlights - Qian Dama has submitted its IPO application to the Hong Kong Stock Exchange, focusing on fresh food retail in the South China market, with a GMV of 9.8 billion yuan in 2024, significantly outperforming its competitors [24][25] - The company operates 2,983 stores, with 2,898 being franchise stores, contributing over 90% of its revenue [25][31] - The report recommends several companies based on their performance and market positioning, including: - Chaohongji, expected to achieve a net profit of 436-533 million yuan in 2025, driven by brand upgrades and channel expansion [39][43] - Meilitiantian Medical Health, projected to see a revenue increase of 28.2% in FY2025H1 [39] - Zhou Dafu, focusing on product structure optimization and store upgrades [39] Investment Themes - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Chaohongji and Laopu Gold [6][37] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [6][37] - Investment Theme 3: Highlight domestic beauty brands that meet emotional value and safety innovation, recommending Maogeping and Pola [6][37] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][37]

Core Viewpoint - The article discusses the rise of medical tourism in China, highlighting the integration of healthcare services with travel experiences, driven by policies like the 240-hour visa-free transit and the "Healthy China 2030" strategy, which aims to make healthcare services more accessible and appealing to international visitors [5][14]. Group 1: Medical Tourism Growth - The implementation of the 240-hour visa-free policy has led to a significant increase in foreign visitors to China, with 40.6 million arrivals in the past year, marking a 27.2% year-on-year growth [5]. - Chinese hospitals, particularly in major cities like Beijing, Shanghai, and Shenzhen, are increasingly catering to international patients, offering competitive pricing and efficient services compared to Western countries [8][13]. - The cost of medical procedures in China is significantly lower than in the U.S.; for example, a heart bypass surgery costs approximately $40,000 in China compared to $130,000 in the U.S. [8]. Group 2: Unique Offerings and Experiences - Chinese hospitals are not only providing medical services but also integrating cultural experiences, such as traditional Chinese medicine, into their offerings, which enhances the appeal for international tourists [15]. - The article highlights successful cases of foreign patients receiving treatment in China, showcasing the effectiveness and affordability of the services provided [7][14]. - The combination of medical treatment and tourism is creating a unique experience that is gaining recognition among international visitors, with some even traveling to China for childbirth [14]. Group 3: Future Projections and Market Potential - The medical tourism market in China is projected to exceed 300 billion yuan by 2029, driven by the dual forces of the "Healthy China" strategy and rising consumer spending [17]. - The article draws parallels with other countries that have successfully developed their medical tourism sectors, such as Cuba and Japan, indicating that China is still in the early stages of establishing a recognizable global brand in this field [18][25]. - The competition among Chinese cities to become the leading destination for medical tourism is intensifying, with initiatives and standards being developed to enhance service quality and attract more international patients [24][23].

Group 1 - The core point of the news is that Juzi Biotechnology has received approval from the National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in the high-end medical aesthetics regenerative materials sector [1][2] - The newly approved product is intended for injection into the dermis, primarily aimed at improving the smoothness of the cheeks, addressing a clear clinical need with limited supply in the market [1] - This product is the world's first implant that combines "recombinant collagen" and "sodium hyaluronate," potentially creating a new paradigm in facial rejuvenation treatments through a synergistic effect of "immediate filling + long-lasting regeneration" [1] Group 2 - Juzi Biotechnology holds two Class III medical device registration certificates in the medical aesthetics field, both of which have passed a stringent dual review process by the National Medical Products Administration, indicating superior safety, efficacy, and quality control [2] - The company leverages its synthetic biology technology platform to achieve breakthroughs in high-end regenerative materials, aligning with national strategic emerging industry directions [2] - There is an expectation for Juzi Biotechnology to accelerate the launch of more innovative products, contributing to the development of the biomanufacturing industry in China [2]

Core Viewpoint - Four Seasons Pharmaceutical has received approval for six new specifications of its self-developed polylactic acid facial filler, enhancing its market position in the regenerative medical aesthetics sector [1] Group 1: Product Development and Approval - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, expanding the product range beyond the previously approved 45mg, 75mg, and 150mg options [1] - The product, known as "童颜针" (Youthful Needle), utilizes PLLA microspheres to provide both immediate filling and long-lasting regeneration effects, with clinical efficacy lasting up to one year for most patients [1] Group 2: Market Positioning and Competitive Advantage - The addition of new specifications allows for precise matching of diverse anti-aging needs, covering a spectrum from mild to moderate aging, thus catering to different age groups and levels of aging [2] - The multi-specification approach strengthens Four Seasons Pharmaceutical's competitive edge in the rapidly growing global market for facial fillers, creating synergies with its other products like "少女针" (Girl Needle) and "双波射频" (Dual Wave RF) [2] Group 3: Clinical and Operational Benefits - The product's rapid reconstitution feature allows for flexible adjustments in dilution concentration and injection dosage, enhancing treatment efficiency and safety [2] - The expansion of specifications aligns with the industry's shift from standardized treatments to personalized solutions, guiding the sector towards higher quality and precision [2] Group 4: Market Strategy and Growth - Four Seasons Pharmaceutical plans to leverage its extensive network of over 7,000 medical institutions to quickly implement the new specifications in the market [3] - The company aims to drive innovation in aesthetic products by utilizing its pharmaceutical research capabilities, providing safer and more precise anti-aging solutions [3]

Core Viewpoint - Four Seasons Pharmaceutical (00460.HK) has received approval from the National Medical Products Administration for six new specifications of its self-developed polylactic acid facial filler, known as "童颜针" (Youthful Needle), marking a significant advancement in the company's market positioning within the regenerative aesthetic medicine sector [1] Group 1: Product Development - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, which will enhance the product selection spectrum [1] - Prior to this expansion, the product had already been approved in three specifications: 45mg, 75mg, and 150mg bottles, catering to different needs such as preventive management, combination therapy, and comprehensive rejuvenation [1] Group 2: Competitive Advantage - Four Seasons Pharmaceutical is the only company in China that holds compliant regenerative filler products, specifically "少女针" (Girl Needle) and "童颜针" (Youthful Needle), along with three other major medical aesthetic devices: botulinum toxin, hydrating injections, and golden micro-needles [1] - The Youthful Needle utilizes a core component of L-lactic acid (PLLA) microspheres, achieving dual effects of "immediate filling + long-lasting regeneration," with patented technology ensuring uniform microsphere morphology and particle size, demonstrating excellent safety and clinical efficacy [1]

Macro Economic Group - In December, M2 growth was 8.5%, exceeding Wind's expectation of 7.9% and up from 8.0% in November. M1 growth was 3.8%, matching expectations but down from 4.9% in November, indicating a slowdown in money velocity [4] - The total social financing (TSF) in December grew by 8.3%, slightly above the expected 8.2% but down from 8.5% in November. The TSF increment was 2.21 trillion yuan, surpassing the expected 1.82 trillion yuan but down from 2.49 trillion yuan year-on-year [4] - Bank credit in December increased by 910 billion yuan, exceeding the expected 679.4 billion yuan and up from 390 billion yuan in the previous month. However, it was down 800 billion yuan year-on-year [5] Industry Comprehensive Group - Siyi Electric (002028.SZ) reported a revenue of 21.2 billion yuan for 2025, a 37.2% year-on-year increase, with Q4 revenue reaching 7.38 billion yuan, up 46.1%. The net profit attributable to shareholders was 3.16 billion yuan, a 54.4% increase, exceeding market expectations [12] - Guanghe Technology (001389.SZ) forecasted a net profit of 980 million to 1.02 billion yuan for 2025, a growth of 45% to 50.8%. The Q4 net profit was estimated at 280 million yuan, a 50.4% increase, driven by strong demand for server PCB boards [13] Advanced Manufacturing Group - The UK AR7 offshore wind auction resulted in 8.4GW of capacity, exceeding expectations and marking a historical high. This sets the stage for significant supply chain orders in the coming years, with a peak delivery expected between 2028 and 2030 [15] - The State Grid has confirmed a total investment of 4 trillion yuan for the 14th Five-Year Plan, a 40% increase from the previous plan, focusing on accelerating ultra-high voltage construction and enhancing supply chain capabilities [16] Consumer Group - The Financial Regulatory Bureau emphasized the need for financial support to boost consumption and investment, particularly in sectors like real estate, healthcare, and small businesses. This is expected to benefit consumer sectors such as automobiles and home appliances [18] - Juzhi Bio's second collagen medical device has been approved, enhancing the focus on the collagen market, which is gaining traction in aesthetic and skin repair applications [19] - Liufeng Group reported a same-store sales growth of 15% for Q4 2025, driven by increased customer flow and product pricing strategies, indicating strong growth momentum [19]

四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 關於渼顏空間 渼 顏 空 間 是 四 環 醫 藥 精 心 孵 化「一 站 式」新 型 醫 美 平 台，通 過 全 球 化 佈 局、全 面 專 業 的 醫 美 產 品 矩 陣、產 品 研 發、註 冊、生 產 及 銷 售 一 體 化 架 構，致 力 於 以 製 藥 企 業 的 嚴 謹 創 新 打 造 匠 心 鑄 造 中 國 醫 美 全 產 品 矩 陣 龍 頭 企 業。渼 顏 空 間 持 續 的 完 整 產 品 矩 陣，管 線 內 共 包 含60餘 款 產 品，覆 蓋 了 包 括 填 充、塑 形、支 撐、 光 電 設 備 及 皮 膚 管 理 類 等 輕 醫 美 的 基 礎 類 別。同 時，渼 ...

Core Viewpoint - CICC maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a 55% upside potential based on 25/23x P/E for 2026-2027 [1] Recent Events - On January 15, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2] - The approval of this product is expected to expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [2] Future Product Pipeline - The company has a rich pipeline for aesthetic medicine, with cross-linked neck wrinkle products receiving priority review status and cross-linked nasolabial fold products progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience expected to enhance future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kemei" collagen repair series and plans for brand upgrades and new product launches in 2026 [4] - In terms of marketing, the company has strengthened its collaboration with key influencers, such as launching a New Year gift box with Li Jiaqi, and plans to enhance its online influencer matrix and self-operated team while expanding offline coverage [4]

Core Viewpoint - Company maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a potential upside of 55% based on 26-27 P/E ratios of 25x and 23x respectively, supported by strong R&D capabilities, brand recognition, and team cohesion [1] Recent Events - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2][3] - The approval is expected to expand the company's aesthetic product matrix and validate its leading technological R&D capabilities [2] Future Product Pipeline - The company has a rich pipeline of aesthetic products, including cross-linked neck wrinkle products that have received priority review status and cross-linked nasolabial fold products that are progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience that can be reused for future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kefumei Collagen Repair," "Focus," and "Order" series set to launch [4] - The company plans to upgrade the "Keli Jin" brand and introduce new products by 2026, while also enhancing collaboration with key influencers like Li Jiaqi for promotional activities [4] - There is a focus on strengthening online influencer networks and self-operated teams, as well as expanding offline channels including cinema lines, OTC, and CS/KA channel coverage [4]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the composite solution, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million following the announcement [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product matrix and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product portfolio, comprehensive channel network, and refined brand operations [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]